A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)

CONCLUSIONS: After a 2+1 schedule, V114 elicited non-inferior immune responses to 13 shared serotypes and superior responses to the two additional serotypes compared with PCV13, with comparable safety profile. These results support the routine use of V114 in infants.TRIAL REGISTRATION: ClinicalTrials.gov: NCT04031846; EudraCT: 2018-003787-31.PMID:37105892 | DOI:10.1016/j.vaccine.2023.04.036

Source: Vaccine - April 27, 2023 Category: Allergy & Immunology Authors: Federico Martinon-Torres Jacek Wysocki Leszek Szenborn Alfonso Carmona-Martinez Airi Poder Ron Dagan Peter Richmond Christopher Gilbert Marie-Chantale Trudel Sheryl Flores Robert Lupinacci Richard McFetridge Richard T Wiedmann Qiuxu Chen Han Gerrits Natal Source Type: research